Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.53
BMRN's Cash to Debt is ranked lower than
75% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. BMRN: 1.53 )
Ranked among companies with meaningful Cash to Debt only.
BMRN' s Cash to Debt Range Over the Past 10 Years
Min: 0.12  Med: 1.14 Max: No Debt
Current: 1.53
Equity to Asset 0.69
BMRN's Equity to Asset is ranked higher than
52% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BMRN: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
BMRN' s Equity to Asset Range Over the Past 10 Years
Min: -0.66  Med: 0.6 Max: 0.97
Current: 0.69
-0.66
0.97
F-Score: 3
Z-Score: 7.31
M-Score: -2.41
WACC vs ROIC
17.17%
-19.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -58.63
BMRN's Operating margin (%) is ranked higher than
54% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. BMRN: -58.63 )
Ranked among companies with meaningful Operating margin (%) only.
BMRN' s Operating margin (%) Range Over the Past 10 Years
Min: -58.63  Med: -12.42 Max: 13.41
Current: -58.63
-58.63
13.41
Net-margin (%) -46.22
BMRN's Net-margin (%) is ranked higher than
56% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. BMRN: -46.22 )
Ranked among companies with meaningful Net-margin (%) only.
BMRN' s Net-margin (%) Range Over the Past 10 Years
Min: -46.22  Med: -15.44 Max: 54.7
Current: -46.22
-46.22
54.7
ROE (%) -20.91
BMRN's ROE (%) is ranked higher than
61% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. BMRN: -20.91 )
Ranked among companies with meaningful ROE (%) only.
BMRN' s ROE (%) Range Over the Past 10 Years
Min: -141.46  Med: -9.05 Max: 39.6
Current: -20.91
-141.46
39.6
ROA (%) -13.45
BMRN's ROA (%) is ranked higher than
65% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. BMRN: -13.45 )
Ranked among companies with meaningful ROA (%) only.
BMRN' s ROA (%) Range Over the Past 10 Years
Min: -13.45  Med: -4.87 Max: 18.88
Current: -13.45
-13.45
18.88
ROC (Joel Greenblatt) (%) -72.68
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. BMRN: -72.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMRN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -72.68  Med: -13.76 Max: 31.1
Current: -72.68
-72.68
31.1
Revenue Growth (3Y)(%) 10.10
BMRN's Revenue Growth (3Y)(%) is ranked higher than
60% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BMRN: 10.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMRN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.4  Med: 12.6 Max: 97.3
Current: 10.1
-10.4
97.3
EBITDA Growth (3Y)(%) 3.50
BMRN's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BMRN: 3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMRN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.2  Med: 24.7 Max: 519.3
Current: 3.5
-45.2
519.3
EPS Growth (3Y)(%) 4.00
BMRN's EPS Growth (3Y)(%) is ranked higher than
59% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. BMRN: 4.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMRN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4 Max: 36.5
Current: 4
0
36.5
GuruFocus has detected 3 Warning Signs with Biomarin Pharmaceutical Inc $BMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMRN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BMRN Guru Trades in Q1 2016

Andreas Halvorsen 602,116 sh (New)
Spiros Segalas 781,714 sh (New)
PRIMECAP Management 7,350,369 sh (+0.27%)
Signature Select Canadian Fund Sold Out
Louis Moore Bacon Sold Out
Frank Sands 11,561,504 sh (-0.65%)
Jim Simons 132,071 sh (-31.77%)
John Griffin 1,000,000 sh (-35.06%)
RS Investment Management 21,120 sh (-78.72%)
» More
Q2 2016

BMRN Guru Trades in Q2 2016

Joel Greenblatt 3,144 sh (New)
Manning & Napier Advisors, Inc 139,920 sh (New)
Eaton Vance Worldwide Health Sciences Fund 370,500 sh (New)
RS Investment Management 24,250 sh (+14.82%)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
PRIMECAP Management 7,319,319 sh (-0.42%)
Frank Sands 10,918,317 sh (-5.56%)
John Griffin 800,000 sh (-20.00%)
» More
Q3 2016

BMRN Guru Trades in Q3 2016

Ray Dalio 8,926 sh (New)
Steven Cohen 153,700 sh (New)
George Soros 5,734 sh (New)
Andreas Halvorsen 490,304 sh (New)
Jana Partners 52,890 sh (New)
Manning & Napier Advisors, Inc 142,410 sh (+1.78%)
John Griffin 800,000 sh (unchged)
Joel Greenblatt Sold Out
PRIMECAP Management 7,108,129 sh (-2.89%)
Frank Sands 10,221,282 sh (-6.38%)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (-21.07%)
» More
Q4 2016

BMRN Guru Trades in Q4 2016

Jim Simons 39,371 sh (New)
Manning & Napier Advisors, Inc 2,027,930 sh (+1324.01%)
Steven Cohen 526,600 sh (+242.62%)
Andreas Halvorsen 1,398,457 sh (+185.22%)
Jana Partners 93,923 sh (+77.58%)
PRIMECAP Management 7,885,948 sh (+10.94%)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (unchged)
Ray Dalio Sold Out
George Soros Sold Out
Frank Sands 9,380,802 sh (-8.22%)
John Griffin 595,000 sh (-25.63%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:GIKLY, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMY, NAS:TSRO, NAS:SGEN, NAS:VRTX, NAS:ALKS, NAS:JAZZ, NAS:INCY, NAS:UTHR, NAS:EXEL, NAS:IONS, NAS:ACAD, NAS:ARIA, NAS:ALNY, NAS:TECH, OTCPK:ALIOY, NAS:GLPG, NAS:ICPT » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to federal, state, local and foreign regulation.

Top Ranked Articles about Biomarin Pharmaceutical Inc

Low Valuation Ratios Lead to Strong Portfolio Returns Backtesting Ben Graham’s Lost Formula strategy
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market. Read more...
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Investor reports latest quarterly portfolio
Samuel Isaly (Trades, Portfolio), manager of the Eaton Vance Worldwide Health Care Fund (ETHSX), invested in three health care companies and eliminated his position in three others during the second quarter of 2016. An active health care investor, Isaly seeks long-term capital growth in health care companies that have potential for high growth and increased market share. The portfolio manager generally has 80% of his assets in health sciences industries, including biotechnology, pharmaceuticals and medical equipment. Read more...

Ratios

vs
industry
vs
history
P/B 5.83
BMRN's P/B is ranked lower than
71% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BMRN: 5.83 )
Ranked among companies with meaningful P/B only.
BMRN' s P/B Range Over the Past 10 Years
Min: 3.67  Med: 6.7 Max: 27.45
Current: 5.83
3.67
27.45
P/S 14.03
BMRN's P/S is ranked lower than
53% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. BMRN: 14.03 )
Ranked among companies with meaningful P/S only.
BMRN' s P/S Range Over the Past 10 Years
Min: 3.39  Med: 14.4 Max: 31.46
Current: 14.03
3.39
31.46
Current Ratio 4.42
BMRN's Current Ratio is ranked higher than
53% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BMRN: 4.42 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.27 Max: 18.94
Current: 4.42
0.9
18.94
Quick Ratio 3.50
BMRN's Quick Ratio is ranked lower than
54% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. BMRN: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 5.22 Max: 18.77
Current: 3.5
0.82
18.77
Days Inventory 567.63
BMRN's Days Inventory is ranked lower than
96% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BMRN: 567.63 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s Days Inventory Range Over the Past 10 Years
Min: 367.05  Med: 530.66 Max: 751.15
Current: 567.63
367.05
751.15
Days Sales Outstanding 75.43
BMRN's Days Sales Outstanding is ranked lower than
59% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. BMRN: 75.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.96  Med: 74.4 Max: 86.7
Current: 75.43
50.96
86.7

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.70
BMRN's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. BMRN: -8.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.6  Med: -9.1 Max: -3.2
Current: -8.7
-32.6
-3.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 32.80
BMRN's Price/Net Current Asset Value is ranked lower than
91% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. BMRN: 32.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BMRN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.95  Med: 20.64 Max: 208.24
Current: 32.8
2.95
208.24
Price/Tangible Book 8.18
BMRN's Price/Tangible Book is ranked lower than
73% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. BMRN: 8.18 )
Ranked among companies with meaningful Price/Tangible Book only.
BMRN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.13  Med: 7.63 Max: 116.7
Current: 8.18
2.13
116.7
Price/Median PS Value 0.97
BMRN's Price/Median PS Value is ranked higher than
50% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BMRN: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
BMRN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.24 Max: 10.35
Current: 0.97
0.28
10.35
Earnings Yield (Greenblatt) (%) -4.20
BMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. BMRN: -4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMRN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.2  Med: 1.2 Max: 4
Current: -4.2
-4.2
4

More Statistics

Revenue (TTM) (Mil) $1,045
EPS (TTM) $ -2.96
Beta2.05
Short Percentage of Float4.75%
52-Week Range $72.96 - 102.49
Shares Outstanding (Mil)171.99

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,113 1,338 1,524 1,750
EPS ($) -2.08 -0.42 0.12 1.82
EPS w/o NRI ($) -2.08 -0.42 0.12 1.82
EPS Growth Rate
(3Y to 5Y Estimate)
28.00%
Dividends Per Share ($)
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
Piotroski F-Score in the Real World Dec 19 2016 
U.S. Elections: What They Might Mean for Investors - JOHCM Commentary Nov 29 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Spiros Segalas Buys McDonald's, Microsoft, Alibaba May 05 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 

More From Other Websites
BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again? Feb 17 2017
BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017 Feb 15 2017
Gilead Sciences & Bristol Myers: Two Wrongs Make a Right? Feb 08 2017
BioMarin to Attend Three Investor Conferences in 1Q17 Feb 08 2017
Your Guide To 2017's Emerging Pharmaceuticals Catalysts Feb 07 2017
BioMarin sues to stop generic version of its $90K-a-year drug Feb 07 2017
BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on... Feb 07 2017
Coverage initiated on BioMarin Pharm by Morgan Stanley Feb 07 2017
BioMarin's Hemophilia Candidate Included in PRIME Initiative Feb 02 2017
BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene... Feb 01 2017
4 Top Biotech Stocks With Big Upcoming Catalysts Jan 31 2017
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US :... Jan 30 2017
Is BioMarin (BMRN) Well Poised for Growth in 2017? Jan 26 2017
We’re in the year of the biotech buyout, and here are five prime targets Jan 23 2017
Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential Jan 19 2017
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US :... Jan 18 2017
BioMarin CEO: Positive results for hemophilia treatment Jan 09 2017
BioMarin Pharma cites positive results for hemophilia treatment Jan 08 2017
BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th... Jan 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)